Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News

Chimeric Therapeutics - CDH17 CAR T preclinical data featured in Nature Cancer

-- A CAR T targeting the cell surface marker CDH17 (“CDH17 CAR”), currently under development by Chimeric as CHM 2101, is featured in the prestigious journal Nature Cancer, highlighting its strong scientific merit and innovation
-- Preclinical data demonstrates strong evidence of efficacy with complete eradication of CDH17-expressing tumours with no toxicity

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that the discovery and preclinical characterization of a CAR T targeting CDH17, currently under development by Chimeric as CHM 2101 has been published as the cover story for the highly prestigious journal Nature Cancer. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.